Dolutegravir Dosing in Chronic Kidney Disease
No dose adjustment of dolutegravir is required for patients with chronic kidney disease, including those with severe renal impairment (CrCl <30 mL/min) or on dialysis, and the standard dose of 50 mg once daily should be used.
Pharmacokinetic Rationale
Dolutegravir undergoes minimal renal elimination, with less than 1% of the drug excreted unchanged in urine 1. The drug is primarily metabolized hepatically via UGT1A1 with some CYP3A contribution, and 53% is excreted unchanged in feces 1.
Evidence from Renal Impairment Studies
In a dedicated pharmacokinetic study comparing 8 subjects with severe renal impairment (CrCl <30 mL/min) to 8 matched healthy controls, dolutegravir exposure was actually lower in the renal impairment group:
- AUC decreased by 40%
- Cmax decreased by 23%
- C24 decreased by 43%
This paradoxical finding means patients with severe CKD have reduced, not increased, drug exposure—eliminating concerns about drug accumulation or toxicity.
Population Pharmacokinetic Data
Population pharmacokinetic analyses from the SAILING and VIKING-3 trials confirmed that mild and moderate renal impairment had no clinically relevant effect on dolutegravir exposure 1.
Practical Dosing Algorithm
- eGFR ≥30 mL/min/1.73 m²: 50 mg once daily (standard dose)
- eGFR <30 mL/min/1.73 m²: 50 mg once daily (no adjustment needed)
- Dialysis patients: 50 mg once daily (though FDA notes "inadequate information to recommend appropriate dosing" for dialysis, the pharmacokinetic data support standard dosing) 1
Important Caveat
The FDA label states there is "inadequate information to recommend appropriate dosing of dolutegravir in patients requiring dialysis" 1. However, given the minimal renal elimination and the fact that severe renal impairment results in lower rather than higher drug levels, standard dosing remains appropriate from a safety perspective. The primary concern would be potential underdosing rather than toxicity.
Effect on Renal Function
Dolutegravir itself causes a reversible decrease in creatinine clearance (9% with 50 mg once daily, 13% with 50 mg twice daily) by inhibiting tubular secretion of creatinine without affecting actual glomerular filtration rate 1. This is a measurement artifact, not true kidney injury, and should not prompt dose reduction or discontinuation.